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Abstract
Purpose Well-designed pharmacoepidemiology studies ad-
dress several limitations of postmarketing spontaneous reports
in regard to signal evaluation. This study evaluated a signal of
disproportionate reporting of acute pancreatitis cases observed
in patients with ulcerative colitis (UC) treated with MMX
Multi Matrix System® (MMX®) mesalazine and demonstrat-
ed how inherent limitations of postmarketing reports were
overcome.
Methods Adults with UC who were new users of MMX
mesalazine or another branded mesalazine (controlled-release,
delayed-release, or extended-release mesalazine; balsalazide
disodium; olsalazine sodium; sulfasalazine; or sulfasalazine
delayed-release) were identified from a large US administra-
tive healthcare claims database. Acute pancreatitis incidence
rates were compared between patients on MMX mesalazine
versus comparator therapies. Propensity scores were used to
match patients on MMXmesalazine with patients on compar-
ator drugs to achieve a balance of baseline patient factors.
Results Crude incidence rates [95 % confidence interval (CI)]
of acute pancreatitis among patients on MMX mesalazine
were similar to those of patients on comparator therapies
[8.55 (5.54–13.21) vs 10.05 (7.54–13.41) per 1000 person-
years]; the resulting incidence rate ratio (IRR) was [0.85
(0.48–1.47)]. Propensity score-matching had little influence
on the IRR [0.84 (0.46–1.55)]; nor did further adjustment by
demographic characteristics, daily dose, and causes of acute
pancreatitis [0.76 (0.41–1.43)].
Conclusion Findings of no increase in pancreatitis risk with
MMX mesalazine demonstrate the value of pharmaco-
epidemiology studies for evaluating a drug’s postmarket safe-
ty profile when confronted with spontaneous reporting data
suggestive of a safety issue.
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Introduction
Given limited sample sizes, short duration, and lack of gener-
alizability of preapproval clinical trials, a drug’s safety profile
at the time of regulatory approval is often incomplete. There-
fore, postmarketing safety surveillance is an essential exercise
in detecting and evaluating adverse drug reactions (ADRs) of
a given drug [1]. The primary source of postmarket safety
surveillance data is voluntary reporting by clinicians and
consumers [2]. Although now computerized, the spontaneous
reporting system has been in place in the United States since
the 1950s [3]. Strengths of the system include the potential to
encapsulate rich clinical details on a single case and the ability
to detect rare ADRs (<1:1,000) compared with clinical trials
[3]. However, limitations of the system are well recognized
and include incomplete reporting, the presence of reporting
biases that may result in both under- and overascertainment,
the lack of a denominator for balanced comparisons, and the
inability to determine incidence rates (IRs) from spontaneous
reports [3].
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In this paper, we present an example of how disproportion-
ate reporting of pancreatitis cases associated with the
pos tmarket surve i l lance of MMX Mult i Matr ix
System®,1(MMX®,1) mesalazine, a 5-aminosalicylic acid
(5-ASA) formulation, was further investigated using a
pharmacoepidemiology study. Treatment with 5-ASA is con-
sidered first-line therapy for patients with active mild to mod-
erate ulcerative colitis (UC) [4]. MMX mesalazine is a once-
daily formulation of 5-ASA administered orally that is effec-
tive in induction and maintenance of UC remission [5–8].
Mesalazine is also available in the United States in several
other formulations (i.e., controlled-release mesalazine,
delayed-release mesalazine, extended-release mesalazine,
balsalazide disodium, olsalazine sodium, sulfasalazine, or
sulfasalazine delayed release).
Acute pancreatitis is an inflammatory disease of the pan-
creas characterized by severe acute upper abdominal pain and
elevated blood levels of serum amylase and/or lipase [9].
Annual incidence of acute pancreatitis is estimated to be
32 cases per 100,000 persons in the general population [10].
Although rare, pancreatitis is an event associated with UC as
well as with mesalazine treatment of UC [11, 12]. As such,
pancreatitis events were observed during clinical development
and postmarketing experience of MMX mesalazine, and this
class effect is listed in its US package insert [13]. Analysis of
reports received by the manufacturer and entered into the
postmarketing surveillance database revealed a higher rate of
reporting for pancreatitis with MMX mesalazine (21.0 cases
per 100,000 person-years of exposure) compared with
controlled-release mesalazine (1.3 cases per 100,000 person-
years) [data on file]. In addition, the US Food and Drug
Administration (FDA) Adverse Event Reporting System Da-
tabase [14] also revealed this pattern of disproportionate
reporting. However, due to the aforementioned reporting
biases, the large differences in the time these drugs have been
on the US market (MMX mesalazine launch in 2007,
controlled-release mesalazine in 1993, and delayed-release
mesalazine in 1992) and other limitations in spontaneous
reporting systems, further investigation was undertaken to
determine whether the reporting data indicated a true asso-
ciation of pancreatitis with MMX mesalazine compared
with other mesalazine formulations. A summary of the
findings from the postmarketing spontaneous reporting
data and the associated limitations in interpretation is presented
in Table 1.
One strategy to investigate whether spontaneous ADR
reports reflect a true association in the rate of pancreatitis with
MMX mesalazine is to conduct a pharmacoepidemiology
study with healthcare claims data [2]. The use of electronic
healthcare data to monitor drug safety has evolved in recent
years, as evidenced by the FDA’s Sentinel Initiative, a long-
term program designed to build and implement a national
electronic system for monitoring the safety of FDA-
approved drugs [15]. The purpose of this paper is to describe
a pharmacoepidemiology study designed to evaluate a signal
observed in spontaneous reporting data for acute pancreatitis
in patients with UC using MMX mesalazine, and to report on
the methods and findings of this study and how it overcame
the limitations of the postmarketing reports.
Methods
Study design
This retrospective cohort study analyzed US pharmacy and
medical claims data from the Thomson Reuters (Truven
Health) MarketScan® Commercial and Medicare supplemen-
tal claims databases. They are fully integrated patient-level
databases covering healthcare delivery from the inpatient,
outpatient, drug, and laboratory settings, as well as health risk
assessment, and benefit design information from US commer-
cially insured and Medicare supplemental populations. The
MarketScan databases are compliant with the Health Insur-
ance Portability and Accountability Act of 1996. Patient data
provided by Truven Health were de-identified; therefore, per
International Society for Pharmacoepidemiology Guidelines
on Data Privacy, Medical Record Confidentiality, and Re-
search in the Interest of Public Health [16], no Internal Review
Board approval or patient authorization was required.
Using these databases, patient and treatment information
was obtained for all patients with any diagnosis of UC
[International Classification of Diseases, 9th revision, (ICD-
9) 556, 556.0, 556.1, 556.5, 556.6, 556.8, and 556.9] between
1 July 2007 and 1 December 2010. Given the objective of this
study, MMX mesalazine was considered the treatment of
primary interest. Comparator drugs consisted of all other
branded orally administered mesalazine-containing medica-
tions indicated for UC. Comparator 5-ASA UC drugs were
combined into one category, which was subdivided into cate-
gories according to the specific mechanism of 5-ASA release:
moisture dependent (controlled-release mesalazine), pH-
dependent (delayed- and extended-release mesalazine), and
azoreductase dependent (balsalazide disodium, olsalazine so-
dium, sulfasalazine, and sulfasalazine delayed release). The
comparator drugs were restricted to branded, orally adminis-
tered UC medications; suppositories and generic forms were
not used as comparators. The rationale for these restrictions
was to minimize potential bias when comparing MMX
mesalazine (available as branded and for oral administration
only) due to channelling of patients to older and less expensive
UC drugs. The baseline period was defined as the 6-month
interval prior to the initial dispensing of one of the study drugs.
1 MMXMulti Matrix System® and MMX® are registered trademarks of
Cosmo Technologies Ltd., Wicklow, Ireland.
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Follow-up began on the index date, defined as the first day of
initial dispensing of a study drug after the 6-month drug-free
interval, and continued until treatment discontinuation of index
mesalazine treatment, date of first pancreatitis event,
disenrollment from the database, or the end of the study period
(31 December 2010).
The main study outcome was acute pancreatitis (ICD-9:
577.0) occurring within the exposure episode, which was
defined as the period from the index date through 30 days
following the days’ supply of the last prescription. Discontin-
uation was defined by determining the days between each
consecutive pair of prescriptions; if this timeframe was longer
than the days’ supply plus 30 days, then the patient was
considered to have discontinued the index drug. Additionally,
after 30 days from the days’ supply of the last prescription of
the index drug, the patient was also defined as discontinued.
As patient follow-up was censored in parallel with index drug
discontinuation, there was no risk of any patient having ex-
posure to multiple study drugs during follow-up. Per algo-
rithms applied in prior database studies, acute pancreatitis
must have been associated with a hospital/emergency room
(ER) visit [17, 18]. Based on the claims-based algorithm in
another study that produced the highest positive predictive
value (82.2 %) for acute pancreatitis, if both chronic and acute
pancreatitis were recorded in the same admission/ER visit, the
event was assumed to be chronic pancreatitis [18]. Patients
were censored from further follow-up after acute pancreatitis
was diagnosed.
Patient population
Eligible participants in this study were adults aged ≥18 years
diagnosed with UC within 6 months prior to receiving one of
the study drugs. Patients were required to be new users of
MMX mesalazine or a comparator 5-ASA UC treatment and
were categorized by the first mesalazine drug received. New
users were defined as patients with one prescription or more
for a study drug, with no prior use of MMXmesalazine or any
of the comparator UC treatments in the previous 6 months,
ensuring that the patient drug cohorts were mutually exclu-
sive. The inclusion criteria used to identify patients were
aligned with patient selection criteria in prior retrospective
UC database studies [19–22]. Patient eligibility criteria for
this analysis are provided in the Supplementary Table 1. To
control for confounding by indication, analyses were also
conducted on a propensity-matched set, wherein each patient
from the MMX mesalazine cohort was matched one to one
with a comparator patient by decile of propensity scores (i.e.,
the probability of being prescribed MMX mesalazine versus
comparator, regardless of actual drug received). MMX
mesalazine users not matched to a comparator were excluded
from the propensity-matched set.
Statistical analyses
Patient identification and the majority of analyses were con-
ducted using SÆfetyWorks® software (UBC Corporation,
Table 1 Postmarketing spontaneous reporting data for pancreatitis with MMX® mesalazine
Findings from spontaneous reporting systems
Shire Global Safety Systema [data on file] • Higher rate of reporting for pancreatitis with MMX mesalazine (21.0 cases per 100,000 person-
years of exposure) compared with another marketed controlled-release mesalazine formulation
(controlled-release mesalazine; 1.3 cases per 100,000 person-years)
US FDA Adverse Event Reporting System
(AERS) database [14]
• Disproportionate reporting of pancreatitis for MMX mesalazine compared with controlled-release
mesalazine and delayed-release mesalazine [lower bound of the 95 % confidence interval of the
Empirical Bayesian Geometric Mean (EB05) of pancreatitis cases: 5.78 for MMX mesalazine
compared with 2.05 for controlled-release mesalazine and 1.92 for delayed-release mesalazine]
Limitations in interpretation [2, 3]
• Reporting biases due to the difference in time on the US market of the compared drugs (MMX
mesalazine launch in 2007, controlled-release mesalazine in 1993, and delayed-release mesalazine
in 1992)
• Underreporting overall and differential underascertainment between drugs
• Source population (denominator) is unknown, resulting in inability to calculate true incidence rates
• Incomplete reporting of patient covariates required to adjust for confounding
• Incomplete supporting data to validate or adjudicate endpoints
FDA Food and Drug Administration
a Fully validated safety database utilized for data entry, storage, and analysis of adverse event information received from sources including but not limited
to healthcare practitioners, regulatory authorities, clinical trials, consumers, and the publishedmedical literature. The database allows for aggregate report
production and reporting of individual-case safety reports to regulatory authorities
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Harrisburg, PA, USA). Data were processed into a common
data model format prior to being loaded into the SÆfetyWorks
environment. Because of limitations inherent in the
SÆfetyWorks software, certain analyses (e.g., calculations
and model building involving dose, conducted only for
MMX mesalazine patients and comparators remaining after
propensity-score matching) were conducted outside of the
SÆfetyWorks platform using SAS, version 9.2 (SAS Institute
Inc., Cary, NC, USA).
Unadjusted IRs were calculated as the number of acute
pancreatitis cases per 1,000 person-years of follow-up; unad-
justed IR ratios (IRRs) were calculated as the ratio of the
MMX mesalazine IR to the comparator IR. As a measure of
relative risk, an IRR <1.0 depicts lower incidence among
patients receiving MMX mesalazine. MMX mesalazine IRs
and related IRRs were further stratified individually by age
and sex categories.
Prior to propensity-scorematching, several sensitivity anal-
yses were conducted by varying both the gap between refills
(i.e., drug-persistence gap) and length of the risk period after
the last treatment episode (interval at the end of the supply of
the last prescription, within which a pancreatitis event would
still be included in the study). These analyses were performed
at 15, 30, and 60 days to evaluate the impact of assumptions
about continuous treatment and the risk period to the unad-
justed IRs. An explanation of propensity score methodology is
provided in Supplementary Table 2.
Adjusted IRRs were estimated from the propensity-matched
data set using a Poisson regression model, with the log of
follow-up time as an offset parameter. To achieve balance in
baseline risk, each patient in the MMX mesalazine cohort was
matched to a comparator by propensity scores within the same
decile of the propensity-score-distribution. After matching, IRR
analyses comparing MMX mesalazine to comparators were
conducted without further adjustment (i.e., propensity-score–
matched only) and also using two further adjusted models (to
control for possible residual confounding). The first adjusted
model incorporated age group (18–29, 30–39, 40–49, 50+),
gender, and continuous average daily dose measure. The sec-
ond adjusted model also incorporated risk factors of acute
pancreatitis, consistent with Frossard et al. [23]. Of note, not
all variables were included in the final model; ones that were
weakly associated in unadjusted models (P>0.5) and collinear
variables were excluded. Ultimately, only six of 49 possible
variables were in final models. Propensity-matched sets were
used for all adjusted analyses, whereas the entire study sample
was used for unadjusted (crude) analyses.
For MMX mesalazine and comparators, the dose of each
prescription was calculated on a per-patient basis as the num-
ber of pills dispensed multiplied by the medication strength in
the propensity-matched set only. MMX mesalazine and com-
parators delayed-release, controlled-release, and extended-
release mesalazine, as well as olsalazine, were considered to
be in equivalent units of mesalazine. Mesalazine conversion
factors were used to equate doses of balsalazide and
sulfasalazine with the other mesalazines: 6,750mg balsalazide
and 6,200 mg sulfasalazine were considered roughly equiva-
lent to 2,400 mg mesalazine [24, 25]. Although it was later
discovered that the conversion for sulfasalazine should have
been 6,000 mg (not 6,200 mg) as equivalent to 2,400 mg
mesalazine, this small error affected 4 % of all comparators
and was deemed not to have had a meaningful impact on dose
classification. After application of the mesalazine conversion
factors, the average daily dose per treatment course for each
patient was calculated as the cumulative dose divided by the
total days of supply, and average daily doses were categorized




A total of 14,936 patients (54 % male) were identified in the
study. Patient demographic and baseline characteristics are
summarized in Table 2. Mean age of the study sample was
46.5 years. Nine (0.06 %) patients were given prescriptions
for both MMX mesalazine and a comparator mesalazine on
their index date. These patients were included in the total
cohort but excluded from both the MMX mesalazine and all-
comparator subgroups.More than 10% of patients with UC in
the MMX mesalazine and 5-ASA comparator groups were
receiving other types of medication at baseline, including
acetaminophen, potassium chloride, hydrocodone, metronida-
zole, other mesalazines, ciprofloxacin, and sodium bicarbon-
ate. The most common preindex medical conditions present in
patients at baseline were gastrointestinal inflammation, diar-
rhea, abdominal pain, rectal hemorrhage, essential hyperten-
sion, and hematochezia, each occurring in >15% of patients in
both the MMX mesalazine and comparator groups.
Crude incidence and relative risk of acute pancreatitis
The primary outcome measured was the occurrence of acute
pancreatitis in patients receiving MMX mesalazine compared
with those receiving comparator mesalazines. Results from
this analysis are provided in Table 3. From study-drug index
date through 30 days postdiscontinuation, 20 and 46 acute
pancreatitis cases associated with a hospital/ER visit were
identified for the MMX mesalazine and comparator groups,
respectively, with 2,338 and 4,576 person-years of exposure,
respectively (Table 3).
The overall crude IR [95 % confidence interval (CI)] of
acute pancreatitis in the MMX mesalazine group was 8.55
(5.54–13.21) per 1,000 person-years compared with 10.05
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(7.54–13.41) per 1,000 person-years in the all comparators
group. In regards to relative risk in the overall population, the
crude IRR (95 % CI) was 0.85 (0.48–1.47), suggesting that no
difference in pancreatitis risk existed prior to adjustment
between the MMX mesalazine and all comparator
groups (Table 3). Among the comparator subgroups by
5-ASA release mechanism, crude pancreatitis IRs (95 %
CI) were lowest in the azoreductase-dependent group
[5.11 (0.90–28.92) per 1,000 person-years] and highest
in the moisture-dependent group [10.88 (2.98–39.68) per
1,000 person-years].
Sensitivity analyses varying both the drug persistence gap
and risk period between 15, 30, and 60 days had little influ-
ence on the overall incidence of acute pancreatitis in the
MMX mesalazine group. Similarly, the IRRs of the MMX
mesalazine and comparator group were relatively stable
(range 0.78–0.89; data not shown).
Adjusted incidence and relative risk of acute pancreatitis
Of the 4,751 patients in the MMX mesalazine group, 4,499
(94.7 %) patients were propensity-score matched to
Table 2 Patient demographic and





Mean age (median), years 44.38 (44.0) 47.44 (47.0) 46.46 (46.0)
Age categories, n (%)
18–19 130 (2.7) 187 (1.8) 318 (2.1)
20–29 740 (15.6) 1,367 (13.4) 2,108 (14.1)
30–39 1,031 (21.7) 1,829 (18.0) 2,862 (19.2)
40–49 1,075 (22.6) 2,172 (21.3) 3,249 (21.8)
50–59 1,013 (21.3) 2,307 (22.7) 3,322 (22.2)
60–69 532 (11.2) 1,451 (14.3) 1,984 (13.3)
70–79 164 (3.5) 534 (5.2) 698 (4.7)
≥80 66 (1.4) 329 (3.2) 395 (2.6)
Gender, n (%)
Female 2,528 (53.2) 5,527 (54.3) 8,060 (54.0)
Male 2,223 (46.8) 4,649 (45.7) 6,876 (46.0)
Index date, n (%)
Year 2008 1,589 (33.4) 3,958 (38.9) 5,549 (37.2)
Year 2009 1,953 (41.1) 3,608 (35.5) 5,566 (37.3)
Year 2010 1,209 (25.4) 2,610 (25.6) 3,821 (25.6)
Common baseline pharmacotherapy (>10% of patients), n (%)
Acetaminophen 904 (19.0) 2,106 (20.7) 3,010 (20.2)
Potassium chloride 1,049 (22.1) 1,827 (18.0) 2,877 (19.3)
Hydrocodone 650 (13.7) 1,596 (15.7) 2,246 (15.0)
Metronidazole 627 (13.2) 1,536 (15.1) 2,165 (14.5)
Other mesalazine 857 (18.0) 1,035 (10.2) 1,893 (12.7)
Ciprofloxacin 546 (11.5) 1,290 (12.7) 1,839 (12.3)
Sodium bicarbonate 560 (11.8) 948 (9.3) 1,508 (10.1)
Common pre-index medical conditions (>10% of patients), n (%)
Gastrointestinal inflammation 1,851 (39.0) 4,035 (39.7) 5,891 (39.4)
Diarrhoea 1,559 (32.8) 3,353 (33.0) 4,913 (32.9)
Abdominal pain 1,110 (23.4) 2,797 (27.5) 3,910 (26.2)
Rectal hemorrhage 1,111 (23.4) 2,131 (20.9) 3,245 (21.7)
Essential hypertension 742 (15.6) 2,047 (20.1) 2,790 (18.7)
Hematochezia 866 (18.2) 1,666 (16.4) 2,534 (17.0)
Gastrointestinal disorder 584 (12.3) 1,107 (10.9) 1,691 (11.3)
Hyperlipidemia 447 (9.4) 1,166 (11.5) 1,613 (10.8)
Hemorrhoids 483 (10.2) 1,007 (9.9) 1,491 (10.0)
Benign colonic neoplasm 485 (10.2) 976 (9.6) 1,463 (9.8)
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Table 3 Acute pancreatitis incidence rates (IR) and incident rate ratios (IRR; crude and adjusted)
Characteristic MMX mesalazine All comparators IRR (95 % CI)a
Crude rates
Events, n 20 46
Person-time, years 2,338.2 4,576.1
IR (95 % CI)b 8.55 (5.54–13.21) 10.05 (7.54–13.41) 0.85 (0.48–1.47)
Age categories, years IR (95 % CI)b
18–29 20.03 (10.15–39.53) 29.70 (18.78–46.94) 0.67 (0.25–1.63)
30–39 10.68 (4.56–25.00) 10.27 (5.20–20.27) 1.04 (0.27–3.60)
40–49 5.52 (1.88–16.22) 4.32 (1.68–11.11) 1.28 (0.19–7.55)
≥50 4.32 (1.68–11.10) 7.06 (4.35–11.47) 0.61 (0.15–1.89)
Gender, IR (95 % CI)b
Female 10.91 (6.37–18.66) 8.94 (5.84–13.66) 1.22 (0.56–2.55)
Male 6.11 (2.96–12.61) 11.23 (7.61–16.58) 0.54 (0.20–1.29)
Adjusted rates
Events, n 20 21
Person-time, years 2,220.07 1,958.90
Propensity-matched IR (95 % CI)b 9.01 (5.81–13.96) 10.72 (6.99–16.44) 0.84 (0.46–1.55)
Adjusted 1 IR (95 % CI)c 4.40 (1.94–9.98) 5.62 (2.57–12.31) 0.78 (0.42–1.46)
Adjusted 2 IR (95 % CI)d 2.37 (0.91–6.15) 3.10 (1.24–7.75) 0.76 (0.41–1.43)
Age categories, years
18–29
Propensity-matched IR (95 % CI)b 21.43 (10.72–42.86) 26.77 (13.93–51.45) 0.80 (0.31–2.08)
Adjusted 1 IR (95 % CI)c 25.17 (10.50–60.33) 32.76 (15.15–70.83) 0.77 (0.29–2.01)
Adjusted 2 IR (95 % CI)d 22.77 (8.52–60.86) 30.66 (12.89–72.96) 0.74 (0.28–1.95)
30–39
Propensity-matched IR (95 % CI)b 11.10 (4.62–26.67) 12.16 (5.06–29.22) 0.91 (0.26–3.15)
Adjusted 1 IR (95 % CI)c 9.06 (1.78–46.10) 10.89 (3.01–39.38) 0.83 (0.21–3.23)
Adjusted 2 IR (95 % CI)d 3.61 (0.42–30.63) 4.35 (0.78–24.29) 0.83 (0.20–3.44)
40–49
Propensity-matched IR (95 % CI)b 5.80 (1.87–17.99) 4.80 (1.20–19.17) 1.21 (0.20–7.24)
Adjusted 1 IR (95 % CI)c 2.13 (0.26–17.66) 1.89 (0.20–17.76) 1.13 (0.18–6.99)
Adjusted 2 IR (95 % CI)d 1.42 (0.13–15.19) 1.25 (0.10–15.80) 1.13 (0.18–7.00)
≥50
Propensity-matched IR (95 % CI)b 4.55 (1.71–12.12) 6.29 (2.62–15.12) 0.72 (0.19–2.69)
Adjusted 1 IR (95 % CI)c 3.56 (0.39–32.19) 4.60 (0.99–21.25) 0.77 (0.16–3.80)
Adjusted 2 IR (95 % CI)d 1.80 (0.17–19.15) 2.26 (0.37–13.86) 0.80 (0.16–3.97)
Gender
Female
Propensity-matched IR (95 % CI)b 11.52 (6.69–19.83) 6.95 (3.32–14.59) 1.66 (0.66–4.15)
Adjusted 1 IR (95 % CI)c 7.72 (3.05–19.55) 4.94 (1.81–13.51) 1.56 (0.61–4.00)
Adjusted 2 IR (95 % CI)d 3.58 (1.12–11.46) 2.35 (0.70–7.83) 1.52 (0.59–3.92)
Male
Propensity-matched IR (95 % CI)b 6.41 (3.06–13.46) 14.70 (8.71–24.82) 0.44 (0.18–1.08)
Adjusted 1 IR (95 % CI)c 2.00 (0.54–7.45) 4.70 (1.43–15.38) 0.43 (0.17–1.07)
Adjusted 2 IR (95 % CI)d 1.05 (0.22–5.10) 2.52 (0.58–10.98) 0.42 (0.17–1.04)
CI confidence interval
aMMX mesalazine relative to all comparators
b Per 1000 person-years
c Adjustment 1, adjusted for age category, gender, and daily dose
dAdjustment 2, adjusted for age category, gender, daily dose, steroids, enalapril, viral herpes, furosemide, sulfasalazine, and post-surgery procedures
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comparators. No pancreatitis events occurred in the un-
matched MMX mesalazine group. After matching, 20 acute
pancreatitis cases were identified in the MMX mesalazine
group, and 21 cases were identified in the all comparators
group. Prior to matching, propensity scores for the MMX
mesalazine and the all-comparator groups were 0.341 and
0.305, respectively, reflecting a 12 % difference. After
matching, the all-comparator group had a mean propensity
score of 0.340, essentially unchanged for the MMX
mesalazine group. Of the 4,499 MMX mesalazine and
4,499 comparator propensity-score–matched patients, 16
MMX mesalazine and 11 comparator patients were missing
information needed to calculate average daily dose; thus,
the following adjusted incidence analyses were conducted on
4,483 MMX mesalazine and 4,488 comparator patients.
The propensity-matched IR (95 % CI) of acute pancreatitis
among patients on MMX mesalazine [9.01 (5.81–13.96) per
1,000 person-years] was comparable with that of comparator
5-ASA formulations [10.72 (6.99–16.44) per 1,000 person-
years]. All propensity-score–matched analyses yielded com-
parable IRRs to the crude IRR. From the model that incorpo-
rated propensity-score matching only, the IRR (95 % CI)
for MMX mesalazine relative to all comparators was 0.84
(0.46–1.55). Propensity-score–matched models further adjust-
ed (age, gender, dose; Adjusted 1) and fully adjusted (steroids,
enalapril, viral herpes, furosemide, sulfasalazine, and
postsurgery procedures added; Adjusted 2) yielded IRRs of
0.78 (0.42–1.46) and 0.76 (0.41–1.43), respectively (Table 3).
Comparisons between MMX mesalazine and comparator sub-
groups defined by 5-ASA release mechanismwere not possible
in the adjusted analyses due to the limited number of events.
Prescribing patterns
MMX mesalazine users were almost always prescribed a
medium average daily dose, whereas nearly one in five com-
parator drug users were prescribed a low daily dose. Average
daily dose was entered into the two further adjusted models
that estimated relative risk. Prescribing pattern data are pre-
sented in Supplementary Table 3.
Discussion
The impetus for conducting this pharmacoepidemiology study
was a signal of disproportionate reporting of postmarketing
pancreatitis cases, suggesting a potentially elevated risk of pan-
creatitis for MMX mesalazine compared with other mesalazine
formulations used to treat UC. Because spontaneous reporting
data lack complete case ascertainment and defined patient
populations in which to compute IRs and are thus subject
to reporting biases, further evaluation of this possible
relationship was warranted. The primary objective of this
pharmacoepidemiology study was to formally evaluate whether
the risk of pancreatitis among patients with UC using MMX
mesalazine differed from the risk among similar patients using
other branded orally administered mesalazine drugs. Results
from this analysis demonstrated that the adjusted IRR was 0.76
(0.41–1.43), which suggests that the risk for pancreatitis is not
elevated for MMX mesalazine. In estimating this relative risk,
confounding factors controlled for in the pharmacoepidemiology
study, but not in the reporting data, included the calendar period
under comparison, age and gender of the patient, and dose, as
well as baseline comorbidity and concomitant medication.
Acute pancreatitis is a multifactorial condition with many
known causes or combination of causes, such as gallstones,
alcohol use, hypertriglyceridemia, and >500 implicated med-
ications [26]. Even for suspected drug-induced pancreatitis, it
is proposed that drugs are most likely a trigger for pancreatitis
in patients with other risk factors [27]. Therefore, given the
nonspecificity of mesalazine as a cause of pancreatitis, and
that this study was comparing MMX mesalazine to other
mesalazine drugs to determine whether MMX mesalazine
was associated with a further elevation in risk, it was extreme-
ly important to control for the multitude of competing risk
factors, most prominently, concomitant medications. The
spontaneous reports did not allow for this control, whereas
in the pharmacoepidemiology study, some of these factors
were used to adjust relative risk estimates.
The other prominent bias in the spontaneous reporting data
for MMX mesalazine and pancreatitis was reporting bias for
MMX mesalazine due to the Webber effect [28]. This bias was
likely present due to the different lengths of time on the US
market between MMX mesalazine (2007) and the comparator
drugs controlled-release mesalazine (1993) and delayed-release
mesalazine (1992). It has been well established that newer drugs
are monitored more closely for adverse effects (AEs) and that
those AEs are more likely to be reported than medications that
have been in long-term use [29].Whereas healthcare claims data
sources are subject to selection biases related to the population
recorded, there is no reporting bias affecting the recording of an
adverse event. Thus, this pharmacoepidemiology study was an
effective means for eliminating that hurdle, which was likely
present in the spontaneous reporting data.
Despite the methodological advantages of using a
pharmacoepidemiologic study to evaluate a signal generated
via spontaneous reporting, several limitations of this analysis
still exist. Pancreatitis is a rare event, so despite the inclusion
of >4,000 patients in each treatment group, adjusted effect
estimates were somewhat imprecise. However, the fully adjust-
ed model revealed an IRR point estimate of 0.76, with an upper
bound of the 95%CI of <1.5, which, if valid, suggests that any
increase in risk is very likely to be small. Another potential
limitation is that the accuracy of ICD-9 codes used to detect
cases of acute pancreatitis may be questioned, as case status
was not validated in hospital records. However, prior research
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has demonstrated that the ability to properly identify acute
pancreatitis using administrative claims data is good; the ICD-
9-CM557.0 codes for acute pancreatitis have demonstrated high
sensitivity (93 %) and good specificity (72 %) when recorded as
the primary diagnosis [30]. The algorithm we used to define an
acute pancreatitis event was similar, suggesting that diagnostic
miscoding was likely minimal. Finally, alcohol consumption is
an important covariate associated with the risk of pancreatitis
[31]. However, because alcohol consumptionmay not be validly
or reliably recorded in healthcare claims data sources [32], it was
excluded from our analysis so as not to introduce bias due to
differences in ascertainment. Because alcohol consumption is
not a contraindication for MMX mesalazine or comparator
drugs, it was assumed that the groups were fairly balanced on
this risk factor; however, without data, this assumption cannot
be confirmed.
Conclusions
The signal of disproportionate reporting of pancreatitis for
patients treated with MMX mesalazine in relation to other
mesalazine medications was not confirmed by a formal
pharmacoepidemiology study. By using healthcare claims
data (that capture healthcare encounters regardless of whether
they were reported as adverse events), the study eliminated
potential spontaneous reporting bias due to time between
launch of MMX mesalazine relative to comparator drugs. In
addition, the study controlled confounding due to risk factors
for pancreatitis (e.g., disease under treatment, concomitant
medications, and comorbid conditions) by propensity-score
matching and multivariate modelling. These findings demon-
strate the value of pharmacoepidemiology studies for evalu-
ating a drug’s postmarket safety profile when confronted with
spontaneous reporting data suggestive of a safety issue.
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